

Around the world of U.S. healthcare in 360 words or less

Center for Healthcare Regulatory Insight

January 15, 2021 | Issue 155

Editor's note

This note is produced every Friday by the <u>KPMG Center for Healthcare</u> <u>Regulatory Insight</u> and is intended to be short and succinct, no more than 360 words, to provide a digestible bite of healthcare and life sciences news from the past week. Please share this email with colleagues and other interested individuals, and encourage them to <u>subscribe to our mailing list</u> <u>here</u>.

We welcome your feedback. Let us know if KPMG can help. Please <u>reply</u> <u>here to me</u>, **Larry Kocot**, principal and national leader, KPMG Center for Healthcare Regulatory Insight or simply reply to this email with any comments or requests.

Subscribe here 🌙

Special Supplements: COVID-19 News and Medicare Enforcement Issue Brief

In light of the continuing daily volume of COVID-19 activity and news, we have summarized <u>COVID-19 news for the week in this special supplement</u>.

In addition, the Center for Healthcare Regulatory Insight published <u>an issue</u> <u>brief examining trends in Medicare Part C & D civil monetary penalties</u> during the Obama and Trump Administrations and what it could mean for enforcement activity in the upcoming Biden Administration.

0

Healthcare regulatory news

CMS <u>finalized</u> the <u>2022 ACA exchange rule</u>, allowing off-exchange enrollment; advocates <u>sued to stop Georgia's 1332 waiver</u>... <u>8,286,871</u> <u>enrolled in 2021 healthcare.gov plans</u>, up 7% from 2020... An <u>IRS final rule</u> <u>clarifies employer</u> HRA responsibilities.

CMS issued its CY2022 MA and Part D final rule... CMS finalized its rule reducing provider/patient burden through prior authorization improvements and streamlined data exchange... CMS finalized a coverage pathway to expedite beneficiary access to breakthrough medical devices... CMS approved Tennessee's Medicaid 1115 waiver, including allowing a closed Medicaid drug formulary... CMS will require 1115 demonstrations to run at least nine months before termination... CMS delayed by two months the filing deadline for provider facility cost reports.

An <u>HHS final rule prevents civil enforcement actions based solely upon</u> <u>guidance</u>... HHS <u>practice guidelines</u> expand the <u>number of providers who</u> <u>can prescribe buprenorphine</u> for opioid use disorder.

FDA issued an "action plan" for <u>regulating Al/machine learning-based</u> <u>medical software</u>... HHS will require an FDA <u>annual report on drug</u> <u>approval timelines</u> and make permanent a waiver of <u>premarket review</u> <u>requirements</u> for certain medical devices.

A Commerce Department proposed rule would bar federal "march-in rights" to combat high drug prices... Trump Administration <u>acknowledged its \$200</u> <u>Medicare drug discount card</u> plan won't happen.

Janet Woodcock will <u>serve as Acting FDA Commissioner</u> to start the Biden Administration.





Healthcare law and policy news

Healthcare-related cases <u>accounted for \$1.8B of the \$2.2B</u> in FY2020 False Claims Act settlements/judgments.

PCMA <u>sued</u> to <u>block implementation</u> of the Part D "rebate rule"... AstraZeneca, Sanofi, and Eli Lilly <u>sued over HHS' advisory opinion</u> on providing 340B discounts to contract pharmacies.

CommonSpirit Health <u>will sell 14 hospitals to Essentia Health</u>... Aspirus Health <u>will purchase 7 hospitals and other facilities</u> from Ascension... Optum <u>signed an MOU to acquire</u> Atrius... Bluebird Bio <u>is spinning off its</u> <u>oncology unit</u>... Sanofi <u>will acquire Kymab (\$1.45B)</u>... Steris will <u>acquire</u> <u>Cantel Medical</u> (\$3.6B)... BeiGene will <u>partner with Novartis on</u> an oncology product... Talkspace <u>will go public through a SPAC merger</u>... FTC <u>ordered major insurers to share claims data</u> for an examination of consolidation impacts on prices.

More than <u>100 pharmaceutical companies</u> reportedly raised prices on 636 drugs (4.99% average) in 2021... 53.6% of <u>behavioral health patients used</u> <u>telehealth</u> mid-March-early May.





Questions or comments, please send to <u>ushcinsight@kpmg.com</u>.

Succeeding in the new reality

Visit the COVID-19 resource center for KPMG analysis, insights, and perspectives.



kpmg.com/socialmedia



Privacy | Legal

You have received this message from KPMG LLP. If you wish to unsubscribe from Around the world of U.S. healthcare in 360 words or less, please click here. If you wish to unsubscribe from all KPMG communications, please click here.

KPMG LLP, 3 Chestnut Ridge Road, Montvale, NJ 07645

© 2020 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. NDP131714-1A

The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization.



COVID-19 News Supplement

Center for Healthcare Regulatory Insight



COVID-19 by the Numbers

There are now over 23.3 million confirmed COVID-19 cases in the US, with a <u>death toll over 385,000</u>... the country is now <u>averaging nearly 250,000 new cases</u> and <u>4,000 deaths/day</u>... COVID-19 deaths have risen 10% or more since last week in 25 states... CDC reported that <u>cases of COVID-19 in children</u>, <u>adolescents</u>, and young adults have increased since this summer... The pandemic is expected to <u>lower</u> <u>US life expectancy by 1.13 years</u> in 2020.

11.9 million COVID-19 <u>vaccine doses have been administered in the US</u>, 39% of total doses distributed to states.

Executive and Administrative Action

HHS Secretary Alex Azar renewed the COVID-19 public health emergency.

HHS Secretary Alex Azar <u>recommended states expand the categories of individuals prioritized</u> to receive COVID-19 vaccines to everyone 65 and older and those 16 and older with <u>one high-risk medical</u> <u>condition</u>, putting up to 152 million Americans in the priority category and widen vaccine distribution to include pharmacies, clinics, and other venues; the federal government will also <u>release second doses of the vaccine</u> that it had been reserving for those who already received the first dose.

President-elect Biden outlined his plans for a <u>\$1.9T COVID-19 relief package</u>, including <u>\$415 billion to</u> <u>directly combat the virus</u> through funding for vaccine distribution, testing, contact tracing, genomic sequencing, supplies and protective equipment, and other measures... Biden will lay out <u>his vaccine</u> <u>distribution plan this afternoon</u>... Biden named former FDA Commissioner <u>David Kessler to lead</u> <u>Operation Warp Speed</u>.

President-elect Biden received his second dose of Pfizer's COVID-19 vaccine.

The Director of the Administration's Supply Chain Task Force <u>said that the US will need 2.2 billion N95</u> <u>masks a year</u> after the pandemic... The federal government <u>purchased an additional 1.25 million doses</u> of Regeneron's COVID-19 antibody cocktail treatment.

The <u>Pandemic Recovery and Preparedness Plan report</u> concluded that FDA <u>needs to react faster</u> to pandemics and other health emergencies.

Beginning January 26, CDC will <u>require all international air passengers to the US</u> to show proof of a recent negative COVID-19 test before boarding their flight.

Healthcare Regulatory News

FDA granted <u>emergency use authorization for Quanterix's</u> COVID-19 antigen test.

Healthcare Law, Business, and Policy News

Senate Democrats <u>urged HHS to provide states with new resources and guidance</u> to correct "significant failures of the COVID-19 vaccine distribution"... Senator Elizabeth Warren urged the Biden Administration to <u>take a series of executive actions to address the pandemic</u>, including those to improve transparency and oversight, address disparities, rectify supply chain issues, and de-politize the response.

An Axios-Ipsos survey found that <u>60% of Americans would likely receive a COVID-19 vaccine as soon as</u> <u>available</u> to them, up from 52% in mid-December... 47% of respondents to a Harris poll believe the COVID-19 <u>vaccine rollout is moving "too slowly."</u>

Dollar General will offer employees four hours of pay if they get the COVID-19 vaccine.

The Rockefeller Foundation <u>contributed \$30 million toward a stockpile of COVID-19 tests</u>, from which states and territories participating in its testing alliance can purchase tests.

Surveillance, Testing, and Treatment

AstraZeneca <u>applied for emergency use authorization</u> in Europe for its COVID-19 vaccine developed with University of Oxford... A UK official involved in approval of the Oxford-AstraZeneca vaccine said <u>it can be</u> <u>80% effective when there are three months</u> between doses.

Moderna said that its COVID-19 <u>vaccine would provide immunity for at least a year</u>; it plans to deliver between 600 million and 1 billion doses of the vaccine in 2021... Moderna's CEO said the US <u>could reach</u> <u>herd immunity</u> by this summer if rollout of Moderna's and Pfizer-BioNTech's vaccine continues as expected.

Early <u>data show</u> that Johnson & Johnson's COVID-19 vaccine provided participants with at least some immunity after one dose, which the company <u>hoped would be as effective as existing two-dose</u> <u>vaccines</u>; however <u>production of the vaccine has slowed</u>, likely pushing back the timeline for meeting initial production projections.

Pfizer and BioNTech plan to produce 2 billion doses of its COVID-19 vaccine this year.

Now that it has fulfilled the federal government's order, Abbott Labs will make its <u>BinaxNOW COVID-19</u> rapid antigen test available to schools, universities, pharmacies, and workplaces.

CDC <u>awarded LabCorp a contract</u> to study and provide genome sequencing of COVID-19 variants.

World Health Organization's (WHO) Chief Scientist <u>said herd immunity to COVID-19 is unlikely this year</u> despite millions of vaccinations... A team of WHO <u>researchers arrived in China</u> to study the virus' origins... A <u>Lancet study</u> of patients hospitalized with COVID-19 in China found that a <u>majority of patients</u> had at least one symptom six months after initial illness.